Authorities in China have granted IASO Biotherapeutics the go-ahead to begin clinical testing of the experimental CAR T-cell therapy equecabtagene autoleucel in people with neuromyelitis optica spectrum disorder (NMOSD), IASO announced. NMOSD is an autoimmune disorder wherein the body’s immune system launches an inflammatory attack that damages parts…
C-CAR168 CAR T-cells
Recent Posts
- Early trial of experimental CAR T-cell therapy seeks people with NMOSD
- Because patients are the reason for the research, we deserve a seat at the table
- Disability in NMOSD patients may worsen even without relapses
- Aging with NMOSD: How I’m facing the future with hope
- Smoking hinders NMOSD relapse recovery, review study shows